LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma
M.W. Lucas, A.M. Menzies, P. Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A Scolyer, B. van de Wiel, Robyn P.M. Saw, A. Kuijpers, A. Torres Acosta, Joyce Sanders, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank (2025). LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.09.069.
